Who is sponsoring NCT05930626?

NCT05930626 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT05930626?

Interventions in NCT05930626: Biomarkers of acrylamide, glycidol, POPs, PFAS.

What condition does NCT05930626 study?

NCT05930626 studies Disease, Cardiovascular Diseases, Cancer, Environmental Exposure.

Is NCT05930626 still recruiting?

NCT05930626 is currently completed. Last updated 5 July 2023.

Last reviewed 2023-07-05 · How we verify

NCT05930626

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers of Acrylamide, Glycidol, POPs, PFAS and Disease Outcomes and OMICs Signatures

Completed Last updated 5 July 2023

What this trial tests

trial testing Biomarkers of acrylamide, glycidol, POPs, PFAS in Disease in 9,254 participants. Completed in 31 December 2008.

Timeline

1 January 1997

Primary endpoint
31 December 2008

31 December 2008

Quick facts

Lead sponsor	Karolinska Institutet
Status	Completed
Study type	OBSERVATIONAL
Enrollment	9,254
Start date	1 January 1997
Primary completion	31 December 2008
Estimated completion	31 December 2008

Drugs / interventions tested

Biomarkers of acrylamide, glycidol, POPs, PFAS

Conditions studied

Disease — all drugs for Disease →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Cancer — all drugs for Cancer →
Environmental Exposure — all drugs for Environmental Exposure →

Sponsor

Karolinska Institutet

Who can join

Eligibility, any sex, with Disease or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the project is to assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with persistent organic pollutants (POPs) and per- and polyflouroalkyl substances (PFAS) using a prospective cohort study utilizing and integrating various 'OMICs' technologies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

OMICs Signatures Linking Persistent Organic Pollutants to Cardiovascular Disease in the Swedish Mammography Cohort.
Schillemans T, Yan Y, Ribbenstedt A, Donat-Vargas C, et al · · 2024 · cited 11× · PMID 38174696 · DOI 10.1021/acs.est.3c06388

Verify or expand the search:

Other recruiting trials for Disease

Currently open trials in the same condition.

NCT06271538 — Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome · Phase 4 · recruiting
NCT06081452 — Public Survey on Breath Testing for Health and Disease · recruiting
NCT06812091 — Human Microbiome Research and Development for Overcoming Pediatric Diseases · recruiting

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05930626 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 5 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05930626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing